price
corpor client peel hunt
nh celebr birthday juli believ clariti strateg fund plan futur
forthcom point subtli chang polit rhetor recent time posit austerity/effici saw wait
list rise one theresa may set plan june deliv fund nh current budget
alongsid recognit fund requir media groundswel surround asset data-us grow
particularli suggest uk begin realis true valu cradl grave single-provid data nh
possess superior payer-driven collect huge benefit could deliv patient care correct
addit suggest way play also feel much like uk begin talk promin
healthcar data expect next see rise ai applic within healthcar uk
suggest way play
healthcar main protagonist uk care provis lead independ hospit group uk
hospit clinic specialist centr provid care nearli patient pa age societi western lifestyl mean
care cost longer recent abandon nh wait time indic increas demand
spire healthcar set new strategi ebitda target believ nh co-work
crucial futur busi plenti opportun remain base discuss nh trend though
struggl see self-pay deliv guid revenu see inher valu watch close see
outcom new strategi trade ev/ebitda vs clinic service-provid peer add tp
document must treat market commun purpos direct prepar accord legal requir
design promot independ research subject prohibit deal ahead dissemin invest research
case miss key healthcar news flow talk
spire healthcar initi coverag
spire healthcar set new strategi ebitda target believ crucial question whether greater
privat patient revenu replac tumultu nh revenu whether group sidestep part symbiot relationship
believ nh co-work crucial futur busi though struggl see self-pay deliv guid revenu
see inher valu spire abl support nh perform target return watch close see outcome/execut new
strategi trade cy ev/ebitda vs clinic service-provid peer initi add recommend tp
motif submit nda antibiot iclaprim fda
mtfb announc complet submit roll submiss new drug applic nda fda antibiot
iclaprim target gram-posit treatment acut bacteri skin skin structur infect absssi line expect
previou compani guidanc next step includ accept window confirm pdufa qualifi
infecti diseas product qidp track design iclaprim receiv prioriti review review period six month instead
standard month year market exclus follow date approv posit step iclaprim journey market remain
recent upgrad oxb back major new gene therapi licens deal oxb grant exclus world-wid licens axov scienc
axon develop commercialis oxb intern pipelin gene therapi parkinson axo-lenti-pd formerli deal worth
potenti upsid futur clinic commerci product suppli oxb receiv up-front payment incl pre-
payment manufactur ii develop mileston iii regulatori sale mileston iv tier royalti
axo-lenti-pd sale deal demonstr power oxb platform-product model rais tp vs previous
abzena seek monetis abzena insid product
abzena provid fund updat follow fy result june compani reiter work capit requir ntm
follow consult major sharehold board decid prioritis potenti partial monetis interest certain abzena insid
product group enter non-bind head term agreement unconnect third parti interest entitl futur
royalti may aris certain undisclos product board continu explor option includ equiti debt financ meet
on-going work capit requir tp attach abzena insid portfolio remain buyer
udg continu deliv consist confirm result
upgrad udg buy recent see told investor result might provid entri point although manag
guid clearli weaker growth ytd experi suggest stori get punish true form result udg
manag under-promis over-deliv much better margin expect sharp lead low mid-singl digit profit beat
group vs estim guidanc also maintain continu believ consist deliveri expect improv
earn qualiti back posit busi mix justifi premium valuat reiter buy recommend
corpor client peel hunt
death tax strain
motif buy complet nda
perspect model refresh
upgrad new gene therapi
model tp recent deal
confirm cfo step-down
udg healthcar buy beat
resili sharp profit outlook
underappreci driver growth
udg underappreci driver growth
like udg strong posit stabl high-vis healthcar servic industri udg undergo
rapid transform align busi myriad opportun aris shake-up
dispos udg suppli chain activ increas focu faster
grow higher-valu add servic rais udg balanc sheet option signific progress
alreadi made reflect udg expand trade multipl see plenti
upsid multipl consensu forecast forecast pre-tax return rise
new valuat methodolog give explicit credit udg strong balanc sheet
demonstr track record value-enhanc invest interim may udg deliv
strong set result confirm guidanc maintain
clinigen posit risk skew upcom trade statement
clinigen due releas trade updat mid-juli end june believ weak
stock sinc report result overdon although result disappoint
clinic trial servic modest contributor group gross profit phase ramp-up
project earli access area unlicens busi meant profil current
year compound investor nervous
stock trade ev/ebitda price-to-earnings ebitda compound-annual-growth-rate
forecast see good entri point ahead trade updat believ outcom
line market gross profit expect suffici start restor investor confid lead
boost share context gross profit capit iq consensu compar
impli gross profit gross profit prior year earli access
even year expect benefit quantum pharma acquisit also absent
oxford biomedica offer low-risk capex-light pure play gene cell therapi revolut
equiti place fund expans bioprocess facil three major deal novarti bioverativ
axov prove oxb platform well posit growth
importantli believ new deal axov along major bioverativ novarti
collabor prove success oxford biomedica lentivir vector platform bioprocess expertis
believ translat sizeabl near-term contract partner oxb grant
exclus world-wid licens axov develop commercialis oxb intern pipelin gene therapi
parkinson axo-lenti-pd oxb receiv up-front payment includ pre-pay
manufactur ii develop mileston iii regulatori sale mileston
iv tier royalti axo-lenti-pd sale updat financi forecast valuat
reflect deal result upgrad tp vs previous
chart one-month ytd total return
corpor client peel hunt
fda approv deal us exposur
tabl top deal valu
chart us exposur compani within coverag measur revenu
gener us
chart healthcar sub-sector perform vs wider
tabl valuat comparison tabl uk small mid-cap healthcar peel hunt coverag
corpor client peel hunt
chart uk healthcar perform vs us eu rel perform
share
multipl comparison complic heterogen sector mani early-stag player
chart ev/sal rel sale growth
chart ev/sal rel sale growth
chart ev/ebitda rel ebitda growth
chart per rel ep growth
chart ev/ebitda rel ebitda growth
chart per rel ep growth
multipl present profit name coverag
chart sector-weight averag multipl forward price-to-earnings ev/ebitda
chart abc multipl forward price-to-earnings ev/ebitda
chart btg multipl forward price-to-earnings ev/ebitda
chart clin multipl forward price-to-earnings ev/ebitda
chart ctec multipl forward price-to-earnings ev/ebitda
chart hik multipl forward price-to-earnings ev/ebitda
chart udg multipl forward price-to-earnings ev/ebitda
chart vec multipl forward price-to-earnings ev/ebitda
corpor client peel hunt
corpor client peel hunt
chart uk healthcar equip servic uk healthcar perform vs uk
corpor client peel hunt
chart us life scienc tool index use proxi reflect wider perform sub-
chart us med-tech index use proxi reflect wider perform sub-sector
corpor client peel hunt
chart us index use proxi reflect wider perform sub-sector
corpor client peel hunt
novarti result
gsk result
astrazeneca result
recommend distribut juli
research publish last day
recommend structur distribut
peel hunt recommend structur follow
buy expect absolut price perform month
add rang expect absolut price perform month
hold rang expect absolut price perform month
reduc rang expect absolut price perform month
sell expect absolut price perform month
nb recommend primari driver analyst view target price may vari structur due market condit risk profil compani capit return
